Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer
Phase 1
Withdrawn
- Conditions
- Colorectal Cancer
- Interventions
- Device: FerroTraceTMDrug: indocyanine green (ICG)
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05092750
Patient-Informed Educational Intervention for the Improvement of Cervical Cancer Literacy
Withdrawn
- Conditions
- Stage IIA Cervical Cancer FIGO 2018Stage IIA1 Cervical Cancer FIGO 2018Stage IB1 Cervical Cancer FIGO 2018Stage II Cervical Cancer FIGO 2018Stage III Cervical Cancer FIGO 2018Stage IIIC2 Cervical Cancer FIGO 2018Stage IB Cervical Cancer FIGO 2018Stage IB2 Cervical Cancer FIGO 2018Stage IB3 Cervical Cancer FIGO 2018Stage IIB Cervical Cancer FIGO 2018
- Interventions
- Other: Educational InterventionOther: Survey Administration
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05093712
Parent and Family Obesity Intervention in Reducing Obesity Risk in Racial Ethnic Minority Families
Not Applicable
Active, not recruiting
- Conditions
- Obesity-Related Malignant Neoplasm
- Interventions
- Behavioral: Behavioral InterventionOther: CounselingProcedure: DiscussionOther: Educational InterventionOther: Informational InterventionOther: Interview
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT05094466
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Myeloma Multiple
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 94
- Registration Number
- NCT05091372
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia (AML)B-Cell LymphomaMyelodysplastic Syndromes (MDS)
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 94
- Registration Number
- NCT05092451
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit
Suspended
- Conditions
- Recurrent Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmLocally Advanced Malignant Solid Neoplasm
- Interventions
- Procedure: ElectroencephalographyOther: Questionnaire Administration
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05091632
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Phase 1
Recruiting
- Conditions
- Advanced Breast CarcinomaAdvanced Endometrial CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Hepatocellular CarcinomaAdvanced Malignant Abdominal NeoplasmAdvanced Malignant Female Reproductive System NeoplasmAdvanced Malignant Thoracic NeoplasmAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaAdvanced Renal Cell Carcinoma
- Interventions
- Drug: Cabozantinib S-malateBiological: AtezolizumabProcedure: Tumor Treating Fields TherapyDrug: Nab-paclitaxel
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT05092373
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation
Active, not recruiting
- Conditions
- Brain Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingProcedure: Multiparametric Magnetic Resonance ImagingOther: Questionnaire Administration
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT05087888
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy
Completed
- Conditions
- Gastric CarcinomaMalignant Peritoneal NeoplasmCarcinomatosisAppendix CarcinomaColorectal CarcinomaMalignant Solid Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Pain AssessmentOther: Questionnaire Administration
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05083338
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART)
Phase 1
Withdrawn
- Conditions
- Cardiac ArrhythmiaCardiacVentricular Tachyarrhythmias
- Interventions
- Device: stereotactic ablative radiotherapy (SABR)Other: Standard of Treatment
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05084391
© Copyright 2025. All Rights Reserved by MedPath